Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cartesian Therapeutics (RNAC) Change in Receivables: 2014-2024

Historic Change in Receivables for Cartesian Therapeutics (RNAC) over the last 10 years, with Dec 2024 value amounting to -$5.0 million.

  • Cartesian Therapeutics' Change in Receivables rose 101.35% to $368,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.1 million, marking a year-over-year decrease of 5852.17%. This contributed to the annual value of -$5.0 million for FY2024, which is 588.43% down from last year.
  • Latest data reveals that Cartesian Therapeutics reported Change in Receivables of -$5.0 million as of FY2024, which was down 588.43% from -$726,000 recorded in FY2023.
  • Cartesian Therapeutics' 5-year Change in Receivables high stood at $2.7 million for FY2021, and its period low was -$5.0 million during FY2024.
  • For the 3-year period, Cartesian Therapeutics' Change in Receivables averaged around -$3.0 million, with its median value being -$3.3 million (2022).
  • Its Change in Receivables has fluctuated over the past 5 years, first soared by 78.12% in 2023, then slumped by 588.43% in 2024.
  • Cartesian Therapeutics' Change in Receivables (Yearly) stood at $2.2 million in 2020, then increased by 20.95% to $2.7 million in 2021, then crashed by 223.35% to -$3.3 million in 2022, then skyrocketed by 78.12% to -$726,000 in 2023, then slumped by 588.43% to -$5.0 million in 2024.